Rev Esp Cir Ortop Traumatol. 2023 Jun 11:S1888-4415(23)00157-1. doi: 10.1016/j.recot.2023.06.010. Online ahead of print.
ABSTRACT
INTRODUCTION: Topical tranexamic acid (TXA) has been shown to decrease blood loss in knee and hip arthroplasty. Despite evidence about its effectiveness when administered intravenous, its effectiveness and optimal dose when used topically has not been established. We hypothesized that the use of 1.5 g (30 mL) of topical TXA could decrease the amount of blood loss in patients after reverse total shoulder arthroplasty (RTSA).
MATERIAL AND METHODS: One hundred and seventy-seven patients receiving a RTSA for arthropathy or fracture were retrospectively reviewed. Preoperative-to-postoperative change in haemoglobin (ΔHb) and haematocrit (ΔHct) level drain volume output, length of stay and complications were evaluated for each patient.
RESULTS: Patients receiving TXA has significant less drain output in both for arthropathy (ARSA) (104 vs. 195 mL, p = 0.004) and fracture (FRSA) (47 vs. 79 mL, p = 0.01). Systemic blood loss was slightly lower in TXA group, but this was not statistically significant (ARSA, ΔHb 1.67 vs. 1.90 mg/dL, FRSA 2.61 vs. 2.7 mg/dL, p = 0.79). This was also observed in hospital length of stay (ARSA 2.0 vs. 2.3 days, p = 0.34; 2.3 vs. 2.5, p = 0.56) and need of transfusion (0% AIHE; AIHF 5% vs. 7%, p = 0.66). Patients operated for a fracture had a higher rate of complications (7% vs. 15.6%, p = 0.04). There were no adverse events related to TXA administration.
CONCLUSION: Topical use of 1.5 g of TXA decreases blood loss, especially on the surgical site without associated complications. Thus, hematoma decrease could avoid the systematic use of postoperative drains after reverse shoulder arthroplasty.
PMID:37311478 | DOI:10.1016/j.recot.2023.06.010
